Construction of a target MSNs drugcarrier loaded with siRNA GLI1 and siRNA SMO aim at hedgehog signal pathway and the pharmacodynamic study of drug-carriers in the treatment of leukemia stem cells

Leukemia stem cells (LSCs) are responsible for leukemia initiation and targeting LSCs is one strategy to treat this disease. This study aims to target LSCs using multi-siRNA loaded antibodies modified with mesoporous silica nanoparticles (MSNs). Here, both siRNA and siRNA were loaded in an anti-CD34...

Full description

Saved in:
Bibliographic Details
Published inDrug delivery and translational research
Main Authors Zhang, Yuan, Cai, Rui, Li, HaiJun, Duan, Yu, Zhang, Yan, Jing, Wei, Lv, ShaoGang, Chu, Xi, Cao, Zheng, Yang, Lei, Ming, Liang
Format Journal Article
LanguageEnglish
Published United States 03.02.2022
Subjects
Targeted treatment
Nano-drug carrier cocktail
Leukemia stem cells
siRNASMO
siRNAGLI1
Online AccessGet more information

Cover

More Information
Summary:Leukemia stem cells (LSCs) are responsible for leukemia initiation and targeting LSCs is one strategy to treat this disease. This study aims to target LSCs using multi-siRNA loaded antibodies modified with mesoporous silica nanoparticles (MSNs). Here, both siRNA and siRNA were loaded in an anti-CD34 antibody modified with MSNs, and then, the MSN@siRNA @Antibody + MSNs@siRNA @Antibody cocktail was used to target LSCs. Expression levels of BCL-2 in LSCs were significantly reduced whereas Bax expression was significantly increased after treatment with nano-drug carriers. In addition, these nano-drug carriers also effectively induced the apoptosis of LSCs. The MSNs@siRNA @Antibody + MSNs@siRNA @Antibody cocktail significantly inhibited LSCs. In short, we constructed two target MSN nano-drug carriers where loaded siRNAs can be used in a chemotherapeutic drug cocktail to improve the treatment of leukemia.
ISSN:2190-3948